ライフサイエンスコーパス: candidemia

1 of Candida in urine (candiduria) and blood (candidemia).

2 ltures when making a definitive diagnosis of candidemia.

3 ified in 18% of 72 patients with C. glabrata candidemia.

4 ths occurred during the hospitalization with candidemia.

5 ocandins are recommended for Candia glabrata candidemia.

6 psilosis is the third most frequent cause of candidemia.

7 n TLR signaling influences susceptibility to candidemia.

8 udied were associated with susceptibility to candidemia.

9 tween infants with candiduria and those with candidemia.

10 r endotoxemia improved survival of secondary candidemia.

11 ogy and burden of early-onset, nonnosocomial candidemia.

12 explained risk factor for the development of candidemia.

13 acing diagnostic uncertainty, or after prior candidemia.

14 n Als3p (rAls3p-N) protects mice from lethal candidemia.

15 s in IDU may be changing the epidemiology of candidemia.

16 an active, population-based surveillance for candidemia.

17 bation, resulting in four missed episodes of candidemia.

18 ed with Klebsiella pneumoniae bacteremia and candidemia.

19 tients with invasive bacterial infections or candidemia.

20 Only 4.6% of patients developed candidemia.

21 g isolate, but it caused only 7% of cases of candidemia.

22 emia are risk factors for the development of candidemia.

23 81%, and 71% of these deaths were related to candidemia.

24 zole as first-line treatment for adults with candidemia.

25 bout OC and endorse routine screening during candidemia.

26 4 years of age and have community-associated candidemia.

27 iagnosis of EE in hospitalized patients with candidemia.

28 regarding ocular screening in patients with candidemia.

29 costs compared to those with only one day of candidemia.

30 e future development of novel treatments for Candidemia.

31 ideal given the complexity of patients with candidemia.

32 shment of definitions of ocular disease with candidemia.

33 ime to mycological clearance and outcomes in candidemia.

34 re diagnosis in critically ill patients with candidemia.

35 ected mice from multidrug resistant C. auris candidemia.

36 in candidemic patients and as predictive of candidemia.

37 an established but uncommon risk factor for candidemia.

38 s in IDU may be changing the epidemiology of candidemia.

39 tation on mortality and clinical outcomes in candidemia.

40 tent effects on antimicrobial resistance and candidemia.

41 ved cytokines to influence susceptibility to candidemia.

42 e 19-44 years, and have community-associated candidemia.

43 ns and was associated with susceptibility to candidemia.

44 magnetic resonance (T2MR), for diagnosis of candidemia.

45 .6% vs. 4.9%, P = 0.000003), and concomitant candidemia (10.4% vs. 7.0%, P = 0.0000004) were associat

46 Of 2176 episodes of candidemia, 128 were CUTS (5.88%).

47 identified 98 783 hospitalized patients with candidemia; 529 patients (0.5%) had concurrent EE.

48 The tests were similar in diagnosing candidemia (59% vs 68%; P = .77), but PCR was more sensi

49 ian (interquartile range [IQR]) detection of candidemia (7.0 [5.0-10.75] h vs 45.5 h [34.25-68.75], P

50 group; P = .005), fewer complications due to candidemia (7.7% vs 33.6% in positive group; P = .008),

51 We detected 773 cases of candidemia, 752 of which were included in the overall co

52 Candidemia, a fungal healthcare-associated infection, ha

53 erapy was observed in patients with C. auris candidemia (adjusted odds ratio, 4.461 [95% confidence i

54 was especially high (34.6%) in patients with candidemia aged 19-44 years.

55 was especially high (34.6%) in patients with candidemia aged 19-44.

56 Sixty-one patients had candidemia alone and 38 patients had combined bloodstrea

57 r patients (P = 0.02) and caused over 25% of candidemias among persons 65 years of age or older.

58 BDG levels were 73.4 pg/ml in patients with candidemia and <10 pg/ml in patients without candidemia

59 ite, 93 African American, 8 other race) with candidemia and 351 noninfected controls (263 white, 88 A

60 We observed strong association between candidemia and a variant, rs8028958, that significantly

61 nazole is associated with a low incidence of candidemia and attributable mortality, despite colonizat

62 tive was to identify factors associated with candidemia and candidemia-related death among adult live

63 diasis (OC) complicates approximately 10% of candidemia and carries potentially severe morbidity.

64 Candidemia and Clostridium difficile infection (CDI) are

65 However, studies of candidemia and COVID-19 coinfection have been limited in

66 002-2014) was used to identify patients with candidemia and EE and their comorbidities.

67 database was used to identify patients with candidemia and EE and their comorbidities.

68 Patients with candidemia and IDU history were younger than those witho

69 ed rezafungin (Rezzayo) for the treatment of candidemia and invasive candidiasis in adults with limit

70 linical trials to be efficacious in treating candidemia and invasive candidiasis.

71 andin under development for the treatment of candidemia and invasive candidiasis.

72 echinocandins in treatment and prevention of candidemia and invasive candidiasis.

73 used for primary treatment and prevention of candidemia and invasive candidiasis.

74 rvention period for the incidence density of candidemia and MDR BSI (+0.018 cases per 1000 OBDs per q

75 ence and mortality rate of hospital-acquired candidemia and MDR BSI through sustained reduction in an

76 and recent surgery commonly associated with candidemia and more likely to have acute risk factors li

77 s diseases or autoimmune diseases, including candidemia and multiple sclerosis.

78 sess the association between the duration of candidemia and outcomes in adult, hospitalized patients

79 on of candidemia relative to a single day of candidemia and outcomes were examined.

80 One subject died at day 24 from candidemia and progressive myeloma, following treatment

81 C. albicans is the most important cause of candidemia and remains highly susceptible to available a

82 More than 70% of patients with candidemia and septic shock were in multiple organ failu

83 differentiation between patients with early candidemia and those without candidemia (ICU patients, i

84 mpared with caspofungin for the treatment of candidemia and/or IC in patients with a positive culture

85 mized trial in patients aged >=18 years with candidemia and/or IC treated with once-weekly intravenou

86 stemic signs and mycological confirmation of candidemia and/or IC were randomized to RZF 400 mg QWk (

87 stemic signs and mycological confirmation of candidemia and/or IC were randomized to RZF 400 mg QWk (

88 was safe and efficacious in the treatment of candidemia and/or IC.

89 nce-weekly echinocandin for the treatment of candidemia and/or invasive candidiasis (IC) was noninfer

90 aspofungin (CAS) once daily for treatment of candidemia and/or invasive candidiasis (IC).

91 scedosporium, zygomycosis, etc.), those with candidemia, and control patients.

92 is of Pneumocystis pneumonia, aspergillosis, candidemia, and endemic mycoses; lack of a standardized

93 s, such as Staphylococcus aureus bacteremia, candidemia, and hepatitis C virus infection.

94 d the first genome-wide association study on candidemia, and we integrated these data with variants t

95 azole (FLC) remains a first-line therapy for candidemia; and voriconazole (VRC), an expanded-spectrum

96 Twenty percent to 70% of all candidemias are associated with this biofilm process.

97 in the rapid identification of 31 out of 72 candidemias as C. albicans and resulted in a significant

98 zole did not statistically alter the rate of candidemia, as this was low across the studies and devel

99 y and allelic scores based on 16 independent candidemia-associated single-nucleotide polymorphisms th

100 We performed prospective surveillance for candidemia at 16 hospitals in the State of Iowa from 1 J

101 those identified with perinatal infections, candidemia, bacteremia, respiratory disorders, or ROP.

102 gistic regression were perinatal infections, candidemia, bacteremia, very low birth weight, prematuri

103 ase chain reaction (PCR) assays can diagnose candidemia before blood cultures and show promising sens

104 There are no current estimates of candidemia burden in the United States (US).

105 ida guilliermondii is an infrequent cause of candidemia but has been associated with decreased suscep

106 We examined the incidence of candidemia, Candida species distribution, and antifungal

107 h initial antifungal treatment for the first candidemia case among adults using multivariable logisti

108 We identified 1226 candidemia cases across 9 surveillance sites in 2017.

109 The proportion of IDU-associated candidemia cases in East Tennessee increased from 6.1% i

110 Candidemia cases involving recent IDU were less likely t

111 Candidemia cases involving recent IDU were less likely t

112 We assessed the proportion of candidemia cases related to IDU during January 1, 2014-S

113 During 2017, 1191 candidemia cases were identified in patients aged >12 ye

114 During 2017, 1191 candidemia cases were identified in patients over the ag

115 Candidemia cases with IDU occurred more commonly in smok

116 Candidemia cases with IDU occurred more commonly in smok

117 nd outcomes among IDU-associated and non-IDU candidemia cases.

118 Plasma BDG levels were undetectable in 18 candidemia cases.

119 e final analysis, including 83 patients with candidemia caused by C. auris.

120 Candidemia caused by Candida spp. is a serious threat in

121 We sought to describe candidemia-CDI coinfection using population-based survei

122 g/dl, respectively, for the 11 patients with candidemia compared to 1.14 and 1.23 microM/mg/dl, respe

123 atheterized patients experiencing persistent candidemia, comparing them to isolates that were cleared

124 Between December 1985 and December 1992, candidemia developed in 1.4% of adult liver transplant r

125 When candidemia develops shortly after abdominal surgery and

126 However, prevalence of candidemia did not differ significantly in two groups (1

127 nt a case report of invasive candidiasis and candidemia due to a Candida glabrata isolate that develo

128 We present the first case of candidemia due to Candida quercitrusa in a pediatric pat

129 We describe marked shifts in candidemia epidemiology over the past 2 decades.

130 Over 18 years, 17 661 candidemia episodes were identified.

131 In 2010, C. kefyr caused 16.7% of candidemia episodes.

132 ortality between days 3 to 30, or persistent candidemia for >/=72 hours after initiation of therapy)

133 Among 536 IE episodes, persistent bacteremia/candidemia for 96 hours (P < .001), and native bone and

134 des with suspected IE, persistent bacteremia/candidemia for 96 hours (P < .001), spondylodiscitis (P

135 d, resulting in up to six missed episodes of candidemia (four Candida glabrata isolates, one C. albic

136 We identified 301 episodes of candidemia from 2001 to 2010 inclusive.

137 We found that nearly 1 in 10 patients with candidemia had CDI coinfection.

138 Candidemia has a high attributable mortality.

139 Delayed treatment of candidemia has previously been shown to be an important

140 U) is a known, but infrequent risk factor on candidemia, however, the opioid epidemic and increases i

141 U) is a known, but infrequent risk factor on candidemia; however, the opioid epidemic and increases i

142 ncluded overall cure (resolution of signs of candidemia/IC + mycological eradication) at day 14 (prim

143 ents with early candidemia and those without candidemia (ICU patients, including Candida-colonized pa

144 ctive, observational cohort of patients with candidemia identified <=72 h of intensive care unit admi

145 y and December 1997 detected 306 episodes of candidemia in 34 medical centers (22 in the United State

146 1997 through 1999 detected 1,184 episodes of candidemia in 71 medical centers (32 in the United State

147 n (BDG) detection assay for the diagnosis of candidemia in children.

148 A growing proportion of candidemia in East Tennessee is associated with IDU, pos

149 Candidemia in ICU patients is caused by non-albicans spe

150 nator, we calculated the annual incidence of candidemia in Iowa to be 6.0 per 100,000 of population.

151 e factors associated with the development of candidemia in liver transplant recipients.

152 , was recently approved for the treatment of candidemia in nonneutropenic patients.

153 n, may help to explain the increased risk of candidemia in patients receiving LE via medical catheter

154 ilant and take proactive measures to prevent candidemia in patients with COVID-19.

155 Clinicians should consider screening for candidemia in people who inject drugs and IDU in patient

156 The Prospective Population Study on Candidemia in Spain (CANDIPOP) is a prospective multicen

157 From 2,675 identified cases of candidemia in the current surveillance, 2,329 Candida is

158 glabrata is the second most common cause of candidemia in the United States, which rapidly acquires

159 nalysis highlights the substantial burden of candidemia in the US.

160 ed cytokine responses, and predisposition to candidemia in whites.

161 re (defined by 7-day mortality or persistent candidemia) in patients treated with either an echinocan

162 We calculated candidemia incidence and antifungal drug resistance comp

163 Candidemia incidence has been rising worldwide following

164 Overall candidemia incidence in East Tennessee was 13.5/100 000,

165 anuary 1, 2014-September 30, 2018, estimated candidemia incidence in the overall population and among

166 associations between significant changes in candidemia incidence rates and guidelines or horizontal

167 changes resulted in a 77.1% reduction in HO candidemia incidence rates since its peak in 2004.

168 antial and sustained systemwide reduction in candidemia incidence rates was observed after the public

169 The first change in HO candidemia incidence rates was preceded by the publicati

170 morbidities that increased the risk of EE in candidemia included endocarditis, cirrhosis, diabetes wi

171 ted blood culture system to detect simulated candidemia, including both Candida albicans and non-albi

172 early incidence of C. kefyr colonization and candidemia increased over the study period (P < 0.01), p

173 cleotide polymorphism increased the risk for candidemia independent of cytokine production.

174 tic data from relevant nonclinical models of candidemia/invasive candidiasis to inform the use of mic

175 Candidemia is a common healthcare-associated bloodstream

176 Candidemia is a common opportunistic infection causing s

177 Candidemia is a severe invasive fungal infection with hi

178 Candidemia is an important cause of morbidity and mortal

179 Prolonged candidemia is associated with worse patient outcomes and

180 Candidemia is common and associated with high morbidity

181 Surveillance for candidemia is conducted in East Tennessee, an area heavi

182 Candida albicans catheter-related candidemia is largely driven by microbial adhesion and b

183 Surveillance for candidemia is necessary to detect trends in species dist

184 Although candidemia is not always found during invasive candidias

185 Candidemia is one of the most common causes of nosocomia

186 Because candidemia is only one form of invasive candidiasis, the

187 3)-beta-D-glucan (BDG) in adults with proven candidemia is unknown.

188 tibility to infections, but its relevance in candidemia is unknown.

189 ivariable analysis showed that patients with candidemia lasting more than one day had significantly h

190 echanisms for differential susceptibility to candidemia may aid in designing host-directed therapies.

191 Patients with IC had candidemia (n = 17), deep-seated candidiasis (n = 33), o

192 The rate of early-onset candidemia nearly doubled between 2000 and 2003 (p < .00

193 on of patients enrolled in a recent study of candidemia, no such clear-cut correlation was present.

194 dence interval [CI], 20 210-25 110) cases of candidemia occurred in the US in 2017.

195 ia treated with insulin up to 2 weeks before candidemia (odds ratio [OR], 16.15; p = 0.002), and 2) e

196 Whether echinocandins could be used to treat candidemia of a urinary tract source (CUTS) is unknown.

197 Candidemia, one of the most common causes of fungal bloo

198 the 245 patients in the primary analysis had candidemia only.

199 nical outcomes included complications due to candidemia or 30-day all-cause mortality.

200 l for the primary treatment of patients with candidemia or invasive candidiasis.

201 ntravenous antibiotics before development of candidemia (OR, 11.15; p = 0.005).

202 ive study included all adults diagnosed with candidemia our tertiary university hospital from 2012-20

203 candidemia and <10 pg/ml in patients without candidemia (P < 0.001).

204 nd potentially antifungal resistant cause of candidemia, particularly among the elderly.

205 A cohort of 338 candidemia patients and 351 noninfected controls were ge

206 We analyzed a retrospective cohort of all candidemia patients at 130 acute care hospitals in the V

207 One-quarter of candidemia patients had COVID-19.

208 Of the 251 candidemia patients included, 64 (25.5%) were positive f

209 il-August 2020 to compare characteristics of candidemia patients with and without a positive test for

210 Candidemia patients with IDU history were younger than t

211 s are associated with persistent fungemia in candidemia patients.

212 Following candidemia, production of specific fungal exotoxins coin

213 ntify factors associated with candidemia and candidemia-related death among adult liver transplant re

214 associations between increasing duration of candidemia relative to a single day of candidemia and ou

215 ominal surgery performed up to 1 week before candidemia (relative risk [RR], 7.25; p = 0.02), high wh

216 Candidemia remains a significant problem in intensive ca

217 udy population with 5% and 10% prevalence of candidemia, respectively.

218 in patients with candidemia who lack typical candidemia risk factors, especially in those with who ar

219 in patients with candidemia who lack typical candidemia risk factors, especially in those with who ar

220 (RR, 0.99; p = 0.02), and elevated AST with candidemia (RR, 1.001; p = 0.01).

221 creening, further supporting current Academy candidemia screening guidelines.

222 Early-onset candidemia seems to be a distinct entity, which is incre

223 ion between IL-17A and kynurenine levels and candidemia suggests their potential as biomarkers for an

224 ns Program conducted active population-based candidemia surveillance at 9 US sites using a standardiz

225 2000, making this the first population-based candidemia surveillance conducted over multiple time poi

226 a case-level analysis using population-based candidemia surveillance data collected through the Cente

227 lates from 33 patients from population-based candidemia surveillance in the United States.

228 Between 2008 and 2011, population-based candidemia surveillance was conducted in Atlanta, GA, an

229 The association of SNPs with both candidemia susceptibility and outcome were assessed.

230 N, I602S) were significantly associated with candidemia susceptibility in whites.

231 Crude in-hospital mortality was higher for candidemia than for bacterial bloodstream infection (28.

232 idering voriconazole therapy for C. glabrata candidemia that occurs in patients with extensive prior

233 For each additional day of candidemia, the adjusted odds of in-hospital mortality i

234 One C. albicans-colonized infant developed candidemia; the colonizing and infecting strains had ide

235 sceptibility testing for timely tailoring of candidemia therapy.

236 The blood of four patients with candidemia, three patients with mixed fungal infections,

237 ted active population-based surveillance for candidemia through the Emerging Infections Program in 45

238 We evaluated IDU-associated candidemia to characterize the epidemiology and estimate

239 Here, we present a mouse model of low-grade candidemia to determine the effect of disseminated infec

240 Outcome for 105 patients with candidemia treated with amphotericin B was correlated wi

241 We describe candidemia treatment practices and adherence to the upda

242 ntation activity, higher annual incidence of candidemia, uncontrolled use of fluoroquinolones, and ro

243 d culture methods, could improve outcomes in candidemia using a desirability of outcome ranking (DOOR

244 at 7 and 30 days after the first episode of candidemia was 16.5% and 47%, respectively.

245 The pretest likelihood of candidemia was 4.4%.

246 days); median voriconazole exposure prior to candidemia was 48 days.

247 e overall mortality rate among patients with candidemia was 81%, and 71% of these deaths were related

248 nd after controlling for other risk factors, candidemia was associated with increased mortality risk

249 Candidemia was cleared in 19.5 and 22.8 hours in RZF and

250 A multicenter study of adult patients with candidemia was conducted in 9 hospitals.

251 Active population-based surveillance for candidemia was conducted in selected US counties.

252 The epidemiology of C. kefyr candidemia was evaluated in another hospital in Montreal

253 Simulated candidemia was produced with 20 Candida isolates at thre

254 ood culture, and 52 control patients without candidemia was reported.

255 In the multivariable model, persistent candidemia was significantly associated with (odds ratio

256 The mortality of inpatients with candidemia was significantly lower in the EE group (2.8%

257 Candidemia was simulated with 15 Candida spp. by using a

258 nced the development of azole resistance and candidemia, weekly mouthwashings were done, and fluconaz

259 The variables predictive of death related to candidemia were abdominal surgery performed up to 1 week

260 and Native American (OR, 5.22) patients with candidemia were at an increased risk of EE developing co

261 Cases of candidemia were categorized as IDU cases if IDU was indi

262 Management strategies for candidemia were compared using an original DOOR analysis

263 f treatment success and 30-day mortality for candidemia were each 51%.

264 A total of 501 patients with bacteremia or candidemia were included in the final analysis: 245 pati

265 A substantial proportion of patients with candidemia were initially treated with fluconazole, resu

266 terial bloodstream infections, patients with candidemia were more likely to have been admitted within

267 = 264) bloodstream infections, patients with candidemia were more likely to have solid tumors (p < .0

268 No associations with susceptibility to candidemia were observed for SNPs in TLR2, TLR4, TLR6, T

269 In the United States, 45% of candidemias were due to non-C. albicans species.

270 the most common species detected, but 43% of candidemias were due to species other than C. albicans.

271 e systems detected all episodes of simulated candidemia when specialized mycology media were used.

272 re timely institution of targeted therapy in candidemia, which can improve patient outcomes.

273 tched case-control study of 26 patients with candidemia, which was defined as the isolation of Candid

274 was used to identify factors associated with candidemia, which were 1) hyperglycemia treated with ins

275 were recovered from 4 patients who developed candidemia while receiving fluconazole and three patient

276 fluconazole and three patients who developed candidemia while receiving voriconazole.

277 n drug use as a risk factor in patients with candidemia who lack typical candidemia risk factors, esp

278 le who inject drugs and IDU in patients with candidemia who lack typical candidemia risk factors, esp

279 This study represented 8599 patients with candidemia who underwent ophthalmologic examination.

280 Controls were patients without candidemia who were randomly selected in a ratio of 5:1

281 We identified 2675 cases of candidemia with 2329 isolates during 3 years of surveill

282 We assessed differences in patients with candidemia with and without a COVID-19 diagnosis.

283 CUTS was defined as a candidemia with concomitant candiduria by the same organ

284 its ability to cause nosocomial and invasive candidemia with high mortality rates.

285 on with the C. albicans clinical isolate vs. candidemia with its agerminative mutant, although serum

286 Candidemia with septic shock is infrequent in nonimmunoc

287 cubated for 5 days, an additional episode of candidemia would have remained undetected.